TQB2868 Injection

DRUG5 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Fudan University

Conditions

Advanced Malignant TumorCervical CancerIntrahepatic CholangiocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPancreatic Neoplasms

Phase 1

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Advanced Malignant Tumor

Start: 2022-04-27End: 2024-06-30Target: 280Updated: 2022-05-02

Phase 2

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

WithdrawnNCT05998941

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Cervical Cancer

Start: 2023-08-31End: 2025-06-30Updated: 2023-11-22

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

RecruitingNCT06767813

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Pancreatic Neoplasms

Start: 2024-03-19End: 2026-11-30Target: 80Updated: 2025-09-19

Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma

Not yet recruitingNCT07846267

Fudan UniversityIntrahepatic Cholangiocarcinoma

Start: 2026-10-01End: 2029-10-01Target: 56Updated: 2026-09-29

Phase 3

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

RecruitingNCT07165951

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2025-12-02End: 2028-12-01Target: 566Updated: 2026-05-29

Related Papers

TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Journal of Clinical Oncology2025-05-28